Highest-materiality recent filing
Baxter Q1 GAAP EPS loss $0.03, adj. $0.36; revenue $2.7B; dividend cut to $0.01
Revenue from continuing operations $2.7B, +3% reported but -1% organic.
Baxter updates on CEO, interim CFO, board refresh, and capital allocation priorities
Andrew Hider appointed President & CEO in Aug 2025; Brent Shafer named Non-Executive Chair.
Baxter CFO Joel Grade departs; Anita Zielinski named interim CFO; full-year 2026 outlook reaffirmed
Joel Grade resigns as EVP and CFO effective March 16, 2026, for personal family reasons; advisory role until April 30.
Baxter Q4 GAAP EPS loss ($2.01), adj. $0.44; sales $2.97B +8%; div cut to $0.01
Q4 sales $2.97B (+8% reported, +3% operational); GAAP diluted EPS loss ($2.01), adjusted diluted EPS $0.44.
Baxter issues $2B in senior notes; launches tender offers for 2026 and 2027 notes
Issued $300M 4.450% notes due 2029, $700M 4.900% notes due 2030, and $1B 5.650% notes due 2035.
Baxter EVP and Group President Alok Sonig resigns effective December 1, 2025
Alok Sonig, EVP and Group President, Pharmaceuticals, notified Baxter of his resignation on Nov 5, 2025.
Baxter Q3 2025: sales $2.84B (+5% reported), GAAP EPS loss $0.10, adj. EPS $0.69
Sales from continuing ops $2.84B, up 5% reported / 2% operational.
Baxter COO Heather Knight resigns effective Oct 29; CEO to assume interim MPT president role
Heather Knight, EVP and COO, resigns to join another healthcare company; effective Oct 29, 2025.
Sales from continuing operations $2.81B, up 4% reported, 1% operational, inline with prior guidance.
Baxter appoints Andrew Hider as CEO, effective on or before Sept 3, 2025
Appointment of Andrew Hider as President and CEO, effective on or before Sept 3, 2025.
Baxter enters $2.2B amended revolving credit facility and $645M term loan amendment
New $2.2B revolver matures June 2030, replacing $2.0B facility and terminating €200M euro facility.
Baxter Q1 beats: sales $2.63B, adj. EPS $0.55; FY guidance raised to $2.47-$2.55
First-quarter sales $2.63B, up 5% reported and operational, exceeding guidance.
Baxter Q4 adj EPS $0.58 beats guidance; Q4 sales $2.75B (+2% CC)
Q4 sales from continuing ops $2.75B, up 1% reported / 2% constant currency, exceeding guidance.
Baxter completes Vantive sale to Carlyle for $3.8B; net proceeds ~$3.4B
Sale closed Jan 31, 2025; Baxter received ~$3.71B cash, net after-tax proceeds ~$3.4B.
Baxter CEO Almeida retires; Brent Shafer appointed interim CEO; Heather Knight named COO
José Almeida retired as CEO/Chair effective Feb 3, 2025; will serve as Special Advisor through Oct 31, 2025.
Sale closed Jan 31, 2025; net pre-tax cash proceeds of approximately $3.71B after working capital and debt adjustments.
Baxter Q3 2024: continuing ops sales +4% to $2.7B; adj. EPS $0.80 beats guidance
Total sales (incl. discontinued ops) $3.85B; continuing ops sales $2.70B +4% YoY.
North Cove facility in Marion, NC closed due to unprecedented flooding from Hurricane Helene on Sept 29, 2024; remediation underway.
North Cove, N.C. plant closed for production due to flood damage; remediation underway.
Baxter CAO Brian Stevens resigns; CFO Joel Grade appointed interim CAO
Brian Stevens resigned as SVP, Chief Accounting Officer and PAO effective Sept 3, 2024; receiving severance per Executive Severance Plan.
Baxter agrees to sell Kidney Care segment (Vantive) to Carlyle for $3.8B cash
Baxter to receive ~$3.5B in cash; net after-tax proceeds ~$3B; to be used for debt reduction.
Baxter Q2 2024 sales $3.81B, adj EPS $0.68 beat; raises full-year guidance
Sales from continuing ops $3.81B, up 3% reported, 4% constant currency, beating prior guidance.
Baxter enters $2.05B credit agreement for refinancing and Kidney Care separation costs
Credit Agreement with JPMorgan, BofA, Citibank provides up to $2.05B senior unsecured term loans.
Q1 sales $3.59B (+2% reported, +3% CC); GAAP EPS $0.07; adj. EPS $0.65, above guidance.
the Board appointed Brent Shafer as interim CEO of the Company and Chair of the Board
Nancy Schlichting was appointed Lead Independent Director
In accordance with the terms and conditions of the Purchase Agreement, effective as of the Closing Date, Chris Toth ceased serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company.
elected Ms. Anita Zielinski as its Senior Vice President, Chief Accounting Officer and Controller, effective as of February 21, 2025
Mr. Joel Grade will cease serving as the Company’s interim Chief Accounting Officer and Principal Accounting Officer and will continue serving as the Company’s Executive Vice President and Chief Financial Officer.
On November 18, 2024, Mr. Peter M. Wilver notified Baxter International Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”) and the Audit Committee and Compensation and Human Capital Committee thereof, effective December 31, 2024.
On September 8, 2024, Baxter International Inc. (the “ Company ”) appointed Jeffrey (Jay) A. Craig to its Board of Directors
On September 3, 2024, the Board of Directors of the Company approved the appointment of Mr. Joel Grade, the Company’s Executive Vice President and Chief Financial Officer, as the Company’s Chief Accounting Officer and PAO on an interim basis, effective September 3, 2024, while continuing to serve in his current position.
On September 3, 2024, Baxter International Inc. (the “ Company ”) and Mr. Brian Stevens mutually agreed that he will resign from his role as the Company’s Senior Vice President, Chief Accounting Officer and Controller and principal accounting officer (“ PAO ”) and will no longer be an employee of the Company as of the same date.
Chris Toth will cease serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company
Max materiality 0.90 · Median 0.60 · Most common event earnings